Abstract:Purpose: To investigate the radiolabeling of E-B5, a monoclonal antibody against Pro-GastrinReleasing Peptide(31-98)by Iodine and study the stability and immunoreactivity of I-E-B5. To determine the in vivo biodistribution of I-E-B5 in normal Kunming mouse and small cell lung cancerbearing nude mouse models(SCLC mouse model) to study the pharmacokinetics of the I-E-B5 in vivo. Characterize the radioimmunoimaging effect and the best imaging time of I-E-B5 in different types of tumors. Methods: I-E-B5 was labeled by chloramine–T method. The labeling efficiency and radiochemical purity were determined by thin-layer chromatography. The I-E-B5 was incubated at 37°C water bath by itself or mixed with normal human serum, the radiochemical purity was then checked at different time points to determine its stability, and the immunoreactivity was determined by cell binding assays.I-E-B5 was injected into the tail veins of the normal Kunming mice which were sacrificed at different time points after injection, and the blood and representative tissues were collected immediately, and the %ID/g (percentage injected dose per gram of tissue) and pharmacokinetic parameters were calculated at various time points. Similarly, T/NT (tumor to non-tumor radioacticity ratio) at various time points were calculated after injection of I-E-B5 into the SCLC model. Mouse models bearing small cell lung cancer, lung adenocarcinoma, colon cancer were utilized to study the radioimmunoimaging effect of I-E-B5, and calculate the T/B ratio (tumor volume to the corresponding location at the other side). Results: I-E-B5 labeling rate was 90.8%, radiochemical purity was 99.28%, and radioactivity was 2.69 MBq/ug. The radiochemical purity of I-E-B5 was 90% after 6 hr at 37°C water bath, and remained at more than 70% after 24 hrs. The radiochemical purity was over 68.1% after 24 hrs mixing with normal human serum. The immunobinding rate of I-E-B5 to NCI-H446 (SCLC cell lines) and A549 (lung adenocarcinoma cell lines) was 71.6%, and 33.2%, respectively. The pharmacokinetics of I-E-B5 is consistent with a two-compartment model with first-order absorption. It was primarily metabolized via liver and kidney. The serum clearance rate is relatively fast. The %ID/g of I-E-B5 in xenografts was dramatically increased to a level much higher than other tissues 48 hrs after injection, reached plateau at 72 hr, and the T/NT ratio was also gradually increased with time. Prominent uptake of I-E-B5 in xenografts of SCLC in nude mice was observed after 24 hrs of injection. The radioactivity in the xenografts was gradually increased with time, and reached the peak at 72 and 96 hr. Xenografts of colon cancer showed similar results as that of SCLC although at a lower level. No observable accumulation was seen in the xenografts of lung adenocarcinoma. The T/B ratio in xenografts of SCLC was consistently higher than in colon cancer at all the time points, and both were significantly higher than that of lung adenocarcinoma which remained stable during the observation duration. Conclusion: The labeling rate and radiochemical purity of I-E-B5 were high and stable both in vivo and vitro. The labeled E-B5 kept its immunologic activity. I-E-B5 selectively accumulated at tumors expressing proGRP, and could effectively target SCLC, therefore is a promising radioimmunoimaging reagent for SCLC.

Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy

Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [111In]dtpa-Hegf and [111In]bz-Dtpa-hegf in Normal Mice

Affibody Molecule for Positron Emission Tomography Imaging of Human Epidermal Growth Factor Receptor: Validation in Mouse Models and Human Cancer Tissues

Characterization of 177Lu-Affibody-hsa Bioconjugate for Radionuclide Therapy of Egfr-Expressing Head and Neck Carcinomas

Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy

177Lu–do3a–hsa–zegfr:1907: Characterization As a Potential Radiopharmaceutical for Radionuclide Therapy of EGFR-expressing Head and Neck Carcinomas

Synthesis and preclinical investigation of 99mTc-p-SCN-Bzl-DTPA-cetuximab for targeting EGFR using head and neck squamous cell carcinoma (HNSCC) xenografts

Studies on the distribution and radioimmunoimaging of 99m Tc-labeled 5-fluorouracil loaded immunological nanoparticles in tissues and human gastric carcinoma xenografts

Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Positive Tumor with a 64cu Labeled Affibody Protein

Epidermal Growth Factor Receptor–Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using 90Y-Labeled Fully Human Antibody Panitumumab

Studies on the Distribution and Radioimmunoimaging of 99mTc-Labeled 5-Fluorouracil Loaded Immunological Nanoparticles in Tissues and Human Gastric Carcinoma Xenografts

Epidermal Growth Factor Receptor–Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using <sup>90</sup>Y-Labeled Fully Human Antibody Panitumumab

Experimental study of pharmacokinetics and radioimmunoimaging of 131 Iodine-labeled monoclonal antibody E-B 5 against Pro-Gastrin-Releasing Peptide ( 31-98 )

131I-recombinant human EGF has antitumor effects against MCF-7 human breast cancer xenografts with low levels of EGFR

177Lu-Labeled Antibodies for EGFR-targeted SPECT/CT Imaging and Radioimmunotherapy in a Preclinical Head and Neck Carcinoma Model.

Transplanted Murine Tumours SPECT Imaging with 99mTc Delivered with an Artificial Recombinant Protein

Synthesis and evaluation of 64 Cu-radiolabeled NOTA-cetuximab ( 64 Cu-NOTA-C225) for immuno-PET imaging of EGFR expression.

Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.

Radioimmunolocalization and blodistribution of 131Ⅰ labeled anti-CEA,TPS and mixture monoclonal antibody in nude mice bearing human breast cancer xenografts

Preclinical Pharmacokinetics and Biodistribution of LR004, a Novel Antiepidermal Growth Factor Receptor Monoclonal Antibody

PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma.